T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Nasdaq
NDAQ
$53.5B
| $72.7M | 0.01% |
2,267,481
-10,107
| -0.4% | -$310K |
|
752
Haemonetics
HAE
$4.16B
| $72.6M | 0.01% |
603,523
+96,335
| +19% | +$9.48M |
|
753
Carpenter Technology
CRS
$26.3B
| $72.6M | 0.01% |
1,513,625
-18,286
| -1% | -$861K |
|
754
Teladoc Health
TDOC
$1.22B
| $72.3M | 0.01% |
1,088,100
-504,767
| -32% | -$29.4M |
|
755
Tidewater
TDW
$4.56B
| $72.2M | 0.01% |
3,076,372
+454,570
| +17% | +$10.5M |
|
756
Maximus
MMS
$2.85B
| $72.2M | 0.01% |
995,746
-7,477
| -0.7% | -$543K |
|
757
Edwards Lifesciences
EW
$53.6B
| $71.8M | 0.01% |
1,166,235
-1,041
| -0.1% | -$62.9K |
|
758
Kosmos Energy
KOS
$1.49B
| $71.6M | 0.01% |
11,426,201
-312,898
| -3% | -$2M |
|
759
UFP Industries
UFPI
$5.06B
| $71.6M | 0.01% |
1,880,714
-46,584
| -2% | -$1.61M |
|
760
Dime Commercial Bancshares
DCOM
$1.81B
| $71.5M | 0.01% |
2,425,652
-3,200
| -0.1% | -$95K |
|
|
ONCE
761
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $71.1M | 0.01% |
694,696
+2,381
| +0.3% | +$257K |
|
762
Red Robin
RRGB
$151M
| $70.5M | 0.01% |
2,306,499
+42,897
| +2% | +$1.32M |
|
763
Highwoods Properties
HIW
$3.46B
| $69.5M | 0.01% |
1,681,827
+346,806
| +26% | +$15.4M |
|
764
Kearny Financial
KRNY
$600M
| $69.4M | 0.01% |
5,219,893
+27,400
| +0.5% | +$368K |
|
765
Endava
DAVA
$162M
| $69.3M | 0.01% |
1,722,012
+1,324,543
| +333% | +$44.7M |
|
766
Portland General Electric
POR
$5.74B
| $68.7M | 0.01% |
1,267,801
-5,171
| -0.4% | -$274K |
|
767
CrowdStrike
CRWD
$226B
| $68.5M | 0.01% |
+4,011,200
| New | +$68.2M |
|
768
Avient
AVNT
$4.16B
| $68M | 0.01% |
2,166,456
-118,497
| -5% | -$3.32M |
|
769
Middlesex Water
MSEX
$1.1B
| $67.9M | 0.01% |
1,145,664
+101,460
| +10% | +$5.9M |
|
770
Allogene Therapeutics
ALLO
$714M
| $67.7M | 0.01% |
2,522,906
+3,398
| +0.1% | +$94.7K |
|
771
Omnicom Group
OMC
$23.5B
| $67.4M | 0.01% |
822,361
+2,588
| +0.3% | +$204K |
|
772
Woodward
WWD
$21.4B
| $67.4M | 0.01% |
595,193
+82,765
| +16% | +$8.87M |
|
773
Eaton
ETN
$179B
| $67.3M | 0.01% |
808,456
-1,024
| -0.1% | -$82.9K |
|
774
Teck Resources
TECK
$32.4B
| $67M | 0.01% |
2,903,585
+424,744
| +17% | +$9.52M |
|
|
MNTA
775
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $67M | 0.01% |
5,378,140
-309,422
| -5% | -$4.11M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.